To continue reading this article, sign up for FREE to
Membership is FREE
and provides you with
instant access
to email newsletters, digital publications, our full content catalogue & more...
Already have an account?
BioFortis and CHI Announce Biorepository Information Technology Strategic Partnership
Read time: Less than a minute
Catholic Health Initiatives' (CHI) Institute for Research and Innovation's Center for Translational Research and BioFortis, Inc. have announced a joint strategic partnership to focus on CHI's vision in personalized healthcare initiatives for community hospitals across their system.
CHI's Center for Translational Research (CTR) is a clinical R&D and molecular diagnostics laboratory that supports the progressive advancement, commercialization, and integration of personalized medicine in CHI's community-based healthcare system. After an in-depth evaluation of existing software solutions on the market, CTR executives concluded that BioFortis' Labmatrix™ would best meet the informatics needs in the areas of workflow-driven protocols, specimen biobanking, next generation diagnostics, biomarker discovery, and translational research.
With the Labmatrix deployment in place, authorized physicians and scientists can explore and ask complex questions about collected data in a unified collaborative environment. This approach is expected to result in faster formulation and better utilization of healthcare intelligence stemming from complementary clinical and specimen-derived molecular assay data.
Furthermore, Labmatrix's security framework ensures protection of highly-sensitive patient information, as well as maintaining regulatory compliance and accountability through a comprehensive audit trail infrastructure. Looking forward, BioFortis and CTR plan to create direct integrations with in-network hospitals' electronic medical records (EMR) systems, and further promote cutting-edge research advancements through secondary use of health data.
CTR National Director, Jeff Otto, PhD, MBA states, "Ensuring the continuity and security of the CTR's annotated biorepository is key to unlocking the knowledge within the samples we collect. Quality biosamples combined with Labmatrix's information technology infrastructure will allow the CTR and its partners to trust the answers that flow from our research, while protecting the privacy of our specimen donors."
CHI's Center for Translational Research (CTR) is a clinical R&D and molecular diagnostics laboratory that supports the progressive advancement, commercialization, and integration of personalized medicine in CHI's community-based healthcare system. After an in-depth evaluation of existing software solutions on the market, CTR executives concluded that BioFortis' Labmatrix™ would best meet the informatics needs in the areas of workflow-driven protocols, specimen biobanking, next generation diagnostics, biomarker discovery, and translational research.
With the Labmatrix deployment in place, authorized physicians and scientists can explore and ask complex questions about collected data in a unified collaborative environment. This approach is expected to result in faster formulation and better utilization of healthcare intelligence stemming from complementary clinical and specimen-derived molecular assay data.
Furthermore, Labmatrix's security framework ensures protection of highly-sensitive patient information, as well as maintaining regulatory compliance and accountability through a comprehensive audit trail infrastructure. Looking forward, BioFortis and CTR plan to create direct integrations with in-network hospitals' electronic medical records (EMR) systems, and further promote cutting-edge research advancements through secondary use of health data.
CTR National Director, Jeff Otto, PhD, MBA states, "Ensuring the continuity and security of the CTR's annotated biorepository is key to unlocking the knowledge within the samples we collect. Quality biosamples combined with Labmatrix's information technology infrastructure will allow the CTR and its partners to trust the answers that flow from our research, while protecting the privacy of our specimen donors."
Add Technology Networks as a preferred Google source to see more of our trusted coverage.
